placeNew Zealand


Only the INVOS system has been proven to be clinically effective in providing clinicians with physiologic insights into a patient’s status to make care-management decisions that contribute to improving patient outcomes.

  • It is the ONLY cerebral oximeter on the market that is validated via a published hypoxia study under different levels of PaCO2.([FOOTNOTE=Kim M, Ward D, Cartwright C, et al. Estimation of jugular venous O2 saturation from cerebral oximetry or arterial O2 saturation during isocapnic hypoxia. J Clin Monit Comput. 2000;16(3):191-99.],[ANCHOR=],[LINK=])
  • Using an optimised emitter spacing configuration, the INVOS system demonstrates sensitivity to subtle changes in saturation and cerebral blood flow.([FOOTNOTE=Hongo K, Kobayashi S, Okudera H, Hokama M, Nakagawa F. Noninvasive cerebral optical spectroscopy. Depth-resolved measurements of cerebral haemodynamics using indocyanine green. Neurol Res. 1995;17(2):89-93.],[ANCHOR=],[LINK=])

Another manufacturer’s disclaimer—accurate when patients are “normal”

A device made by a competitor is designed to determine regional haemoglobin oxygen saturation of blood underneath the sensor, according to the manufacturer.([FOOTNOTE=NONIN Operator’s Manual Model 7600, Page 3, Cautions.],[ANCHOR=],[LINK=]) Its performance and accuracy of the device can be degraded or impacted if the patient’s CO2 levels are non-normocapnic (non-normal) or if there are other conditions that affect blood volume.2

Do your patients always have “normal” CO2 levels?